Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Age-Related Macular Degeneration
Clinical trial register · United States · industry-sponsored

Age-Related Macular Degeneration Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9128 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 04 Nov 2026, 03:16 UTC
9128
Studies in scope
industry-sponsored, all four open statuses
4968
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 9 Illinois 8 Florida 6 Arizona 6 Ohio 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Age-Related Macular Degeneration trials in the USA

17 of 9128 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
Phase 1 Study of C.001 in Retinal Degeneration
NCT07594236Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Cellio Therapeutics Inc
Phase 1
15
California
2026-04-07
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
Recruiting
AbbVie
Phase 1/2
66
Indiana, Nevada, Texas
2025-08-13
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
California, Connecticut, Illinois, Nevada, Ohio, Texas
2025-05-07
Active, closed
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
9
Arizona, Illinois, Tennessee
2025-04-07
Active, closed
Chengdu Origen Biotechnology Co., Ltd.
Phase 1
25
Arizona, Illinois, Massachusetts, Nevada, New Jersey, Tennessee, Texas
2023-10-16
Active, closed
Elisigen, Inc.
Phase 1/2
20
Ohio
2023-09-08
Active, closed
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
Perceive Biotherapeutics, Inc.
Phase 1/2
60
Arizona, California, Massachusetts, Missouri, New Jersey, Oregon, South Dakota, Texas
2023-06-21
Active, closed
ForeseeHome NRich Registry
NCT05690880Age-Related Macular Degeneration
Notal Vision Inc.
Observational
20,000
New Jersey
2022-12-15
Recruiting
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732Age-Related Macular Degeneration, Geographic Atrophy
VisionCare, Inc.
Not applicable
125
California, Florida, Massachusetts, Michigan, Nebraska, New Jersey, North Carolina, Ohio
2022-06-16
Active, closed
Genentech, Inc.
Observational
400
Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2022-05-27
Active, closed
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
NCT05112861Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
Outlook Therapeutics, Inc.
Phase 3
120
Illinois, Maryland, Pennsylvania
2021-11-15
Recruiting
Astellas Institute for Regenerative Medicine
Phase 1
42
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Mississippi
2018-07-13
Recruiting
Stem Cell Ophthalmology Treatment Study II
NCT03011541Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
MD Stem Cells
Not applicable
500
Connecticut, Florida
2016-01
Active, closed
Hoffmann-La Roche
Phase 1/2
24
California, Ohio, Pennsylvania
2015-04-01
Active, closed
Oxford BioMedica
Phase 1
18
Iowa, Maryland, Oregon
2012-08
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 4 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/age-related-macular-degeneration

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,128 studies in total at the last sync on 04 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Age-Related Macular Degeneration.

How many Age-Related Macular Degeneration trials are recruiting in the US?

8 of the 17 studies on this page are recruiting new participants as of the 04 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Age-Related Macular Degeneration), 17 studies
PhaseStudiesRecruitingShare
Phase 15229.4%
Phase 1/24123.5%
Not applicable3317.6%
Observational2011.8%
Phase 2/32211.8%
Phase 3105.9%

Most active sponsors

Lead sponsors with the most studies (Age-Related Macular Degeneration)
Lead sponsorStudiesRecruiting
Chengdu Origen Biotechnology Co., Ltd.20
EyeBiotech Ltd.22
AbbVie11
Astellas Institute for Regenerative Medicine11
Cellio Therapeutics Inc11
Elisigen, Inc.10
Genentech, Inc.10
Hoffmann-La Roche10
i-Lumen Scientific AUS PTY LTD11
MD Stem Cells11

Top states

Top states (Age-Related Macular Degeneration), by number of studies with a site there
StateStudies
California9
Illinois8
Arizona6
Florida6
Massachusetts4
New Jersey4
Ohio4
Texas4
Connecticut3
Indiana3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.